Business Context and Reporting Period
Company: ICU Medical, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2005
Industry: Medical Devices (Disposable I.V. connection systems and critical care devices)
ICU Medical is a leader in proprietary, disposable medical connection systems designed to prevent needlesticks and catheter-related infections. The company's primary product is the CLAVE needleless connector. In May 2005, the company significantly expanded its operations by acquiring Hospira, Inc.'s Salt Lake City manufacturing facility and entering a 20-year Manufacturing, Commercialization and Distribution Agreement (MCDA) to produce critical care devices (catheters, angiography kits) exclusively for Hospira.
Key Financial Metrics
| Metric (in thousands) | 2005 | 2004 | 2003 |
|---|---|---|---|
| Total Revenue | $157,532 | $75,550 | $107,354 |
| Net Sales | $154,621 | $72,704 | $102,726 |
| Gross Profit | $69,404 | $35,697 | $58,910 |
| Gross Margin (vs. Net Sales) | 43% | 45% | 53% |
| Operating Income | $27,595 | $5,912 | $34,124 |
| Net Income | $20,274 | $5,000 | $22,297 |
| Diluted EPS | $1.35 | $0.33 | $1.48 |
| Cash Flow from Operations | $27,372 | $25,283 | $22,829 |
| Cash and Liquid Investments | $86,742 | $87,341 | $73,137 |
| Total Assets | $204,537 | $164,768 | $164,288 |
| Working Capital | $123,875 | $109,590 | $102,932 |
Material Changes vs. Prior Period
- Revenue Surge: Total revenue increased 108% to $157.5 million in 2005 compared to $75.6 million in 2004. This was driven primarily by the May 2005 acquisition of the Hospira Salt Lake City facility, which generated $46.7 million in sales during the remainder of the year.
- Customer Concentration: Sales to Hospira, Inc. increased to 73% of total revenue in 2005 ($115.0 million), up from 53% in 2004. The 2004 decline was due to Hospira reducing its inventory of CLAVE products; 2005 saw a return to normal purchasing levels plus the new MCDA volume.
- Margin Compression: Gross margin decreased to 43% in 2005 from 45% in 2004. Management attributes this to the inclusion of lower-margin critical care products manufactured under the MCDA (averaging 22% margin). Excluding MCDA products, the margin would have been 52%.
- Expense Increases: Selling, General, and Administrative (SG&A) expenses rose to $37.0 million (24% of revenue) from $26.4 million (35% of revenue). The absolute increase was driven by $6.1 million in legal fees related to patent litigation and increased compensation/benefits for the new Salt Lake City facility.
- Balance Sheet: Accounts receivable increased significantly to $23.6 million (from $8.9 million), largely due to new receivables from Hospira under the MCDA. Inventory increased to $15.4 million due to the acquisition of Hospira's inventory and build-up for facility relocations.
Guidance, Outlook, and Risks
- Outlook: Management expects gross margins to improve to 45-46% in 2006 as manufacturing efficiencies are realized at the Salt Lake City plant. SG&A is expected to be 21-23% of revenue in 2006. Capital expenditures for 2006 are estimated at $12.5 million to support facility relocations.
- Strategic Initiatives: The company is relocating molding and automated assembly from California and Connecticut to Salt Lake City, and moving manual assembly to Mexico. These moves are expected to be completed by early 2007.
- Key Risks:
- Customer Dependence: Extreme reliance on Hospira (73% of revenue). Any deterioration in this relationship or Hospira's market position poses a significant threat.
- Manufacturing Relocation: Risks of production interruption, quality issues, or cost overruns during the complex move of operations to Salt Lake City and Mexico.
- Competition: Intense competition from larger firms (Baxter, BD, Cardinal Health/Alaris) and potential price erosion.
- Patent Litigation: Ongoing litigation against Alaris Medical Systems regarding patent infringement; outcomes are uncertain and costs are high.
- Interest Rate Sensitivity: The company holds $86.7 million in liquid investments; low interest rates reduce investment income.
Investor Verification Checklist
- Hospira Relationship Stability: Verify the terms and stability of the 20-year MCDA and the strategic supply agreements with Hospira, given the 73% revenue concentration.
- Margin Trajectory: Monitor whether the projected 45-46% gross margin for 2006 is achieved as the Salt Lake City facility ramps up and costs are optimized.
- Relocation Execution: Track the progress of the manufacturing moves to Salt Lake City and Mexico for any delays or quality disruptions that could impact supply.
- Legal Exposure: Review the status of the patent infringement lawsuit against Alaris Medical Systems and associated legal costs.
- Working Capital Management: Assess the sustainability of the increased accounts receivable and inventory levels required to support the new Hospira volume.